Contribution: Industrial Research Assistance Program – Contributions to Firms
ImmunoVaccine Technologies Inc.
$636,596.00
Covid-19 Response: DPX-COVID-19: Neutralizing-epitope Based Synthetic Vaccine with Potential for Large Scale Production
EF 2020-21 · 2020-04-01
Résumé
This project aims to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company’s DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. IMV believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Dartmouth|Dartmouth, Nova Scotia, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
864736772
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 0 | 2020-04-01 | 2020-21 | $378,239.00 |
| 1 | 2020-04-01 | 2020-21 | $636,596.00 |
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days. The total amended value is 258,357 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 61 jours. La valeur totale des modifications est de 258 357 dollars.
Agreement End Date
2020-12-31
Agreement Number
948901
Agreement Start Date
2020-04-01
Agreement Title
Covid-19 Response: DPX-COVID-19: Neutralizing-epitope Based Synthetic Vaccine with Potential for Large Scale Production
Agreement Title (French)
Réponse à la Covid-19 : DPX-COVID-19 : Vaccin synthétique à base d'épitope neutralisant avec un potentiel de production à grande échelle
Agreement Type
Contribution
Agreement Value
$636,596.00
Amendment Date
2020-07-28
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project aims to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company’s DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. IMV believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine.
Description (French)
Ce projet vise à établir la sécurité clinique et l'immunogénicité d'un candidat vaccin basé sur la technologie d'administration DPX de l'entreprise et incorporant des peptides ciblant de nouveaux épitopes de la souche coronavirus. IMV estime que cette approche basée sur les peptides, combinée à la portabilité de la plate-forme DPX, offre la possibilité d'accélérer le développement et la production rapide et à grande échelle d'un vaccin.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Dartmouth--Cole Harbour
Federal Riding (French)
Dartmouth--Cole Harbour
Federal Riding Number
12004
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
864736772
Recipient City
Dartmouth|Dartmouth
Recipient Country
CA
Recipient Legal Name
ImmunoVaccine Technologies Inc.
Recipient Postal Code
B3B 2C4
Recipient Province or Territory
NS
Recipient Type
F
Reference Number
172-2020-2021-Q1-948901
